Evidence map›Paper›PMID 19887646›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2010

A Pit-1 threonine 220 phosphomimic reduces binding to monomeric DNA sites to inhibit Ras and estrogen stimulation of the prolactin gene promoter.

Annie Jean, Arthur Gutierrez-Hartmann, Dawn L Duval

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Annie JeanDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Anschutz Medical Center, Aurora, Colorado 80045, USA.
Arthur Gutierrez-Hartmann
Dawn L Duval
University of Colorado Denver · US

Funding

PITUITARY-SPECIFIC ONCOGENE SIGNALING MECHANISMSR01DK046868 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GUTIERREZ-HARTMANN, ARTHUR · 1994 to 2006
$2.3M
Signaling Mechanisms Regulating Pituitary Gene ExpressionR56DK070952 · NIDDK · COLORADO STATE UNIVERSITY · PI DUVAL, DAWN L · 2009 to 2010
$577k
PROTEIN INTERACTIONS REGULATING PITUITARY SIGNALINGK01DK002946 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DUVAL, DAWN L · 2001 to 2005
$500k
NIDDK NIH HHS K01 DK002946NIDDK NIH HHS K01 DK02946NIDDK NIH HHS R01 DK046868NIDDK NIH HHS R01 DK46868NIDDK NIH HHS R56 DK070952
6 · The paper itself

Abstract

Pit-1 is a POU-homeodomain transcription factor that dictates the ontogeny of pituitary somatotrophs, lactotrophs, and thyrotrophs through regulation of their respective protein hormone genes: GH, prolactin (PRL), and TSHbeta. Although Pit-1 threonine 220 (T220) and serine 115 are protein kinase phospho-acceptor sites, the transcriptional role of Pit-1 phosphorylation remains unclear. In the rat PRL promoter (rPRL), Ras-stimulated transcription is mediated by binding of Ets-1 and Pit-1 at a composite site (FPIV). Ets-1 and Pit-1 physically interact, and Pit-1 T220 is a major Ets-1 contact point. T220 was mutated to aspartic acid (D, to mimic phosphorylation) or a neutral alanine (A), and DNA binding and transcriptional activity were tested. The Pit-1 T220D mutation reduced binding at monomeric Pit-1 sites (FPIV, PRL-1d), but not dimeric Pit-1 sites (FPI). Pit-1 T220A bound all sites with wild-type (WT) affinity. In transfections of HeLa cells, each Pit-1 mutant transcriptionally activated the -425rPRL promoter and cooperated with Ets-1 to WT levels. In contrast, Pit-1-mediated Ras activation of the -425 rPRL promoter was significantly inhibited by T220D. Finally, Pit-1 synergistic activation of the 2500-bp rPRL promoter with estrogen receptor was reduced by T220D compared with T220A and WT Pit-1. Thus, phosphorylation of Pit-1 T220 reduces binding to monomeric sites blunting Ras and estrogen/estrogen receptor stimulation of the rPRL gene promoter. Consequently, T220 phosphorylation of Pit-1 by protein kinase A, protein kinase C, or cell cycle-dependent kinases appears to serve as a regulatory switch, inhibiting Ras and estrogen/estrogen receptor regulatory pathways, while enhancing the cAMP/protein kinase A response, thus allowing a more precise integration of pituitary responses to distinct signaling stimuli.

Indexed as

Promoter Regions, GeneticAnimalsAspartic AcidCell LineDNA-Binding ProteinsEstradiolHeLa CellsHumansMutant ProteinsMutationOncogene Protein p21(ras)PhosphorylationProlactinProtein BindingProto-Oncogene Protein c-ets-1RatsAspartic AcidDNA-Binding ProteinsEstradiolMutant ProteinsOncogene Protein p21(ras)ProlactinProto-Oncogene Protein c-ets-1Recombinant Fusion ProteinsTranscription Factor Pit-1

Identifiers

PMID19887646
PMCPMC2802898
OpenAlexW1983424335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.